1. J. M.
Llovet
, A. M.Di Bisceglie, J.Bruix, B. S.Kramer, R.Lencioni, A. X.Zhu, M.Sherman, M.Schwartz, M.Lotze, J.Talwalkar, G. J.Gores, for the Panel of Experts in HCC-Design Clinical Trials, J. Natl. Cancer Inst., 2008, 100, 698711
2. R.
Stupp
, W. P.Mason, M. J.van den Bent, M.Weller, B.Fisher, M. J.Taphoorn, K.Belanger, A. A.Brandes, C.Marosi, U.Bogdahn, J.Curschmann, R. C.Janzer, S. K.Ludwin, T.Gorlia, A.Allgeier, D.Lacombe, J. G.Cairncross, E.Eisenhauer, R. O.Mirimanoff, for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group, N. Engl. J. Med., 2005, 352, 987996
3. A holistic approach to targeting disease with polymeric nanoparticles
4. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma
5. Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo